Androgensa | Subject sex | Outcomes | |||||||
---|---|---|---|---|---|---|---|---|---|
12-month AOSI | 36-month SRS | ||||||||
Beta | 95% CI | P | P b | Beta | 95% CI | P | P b | ||
ln(T) | Female (n = 62) | 0.20 | (−0.13,0.53) | 0.22 | 0.95 | −0.05 | (−0.31,0.20) | 0.67 | 0.85 |
Male (n = 75) | 0.22 | (−0.13,0.57) | 0.22 | 0.14 | (−0.19,0.46) | 0.41 | |||
ln(A4) | Female (n = 62) | 0.11 | (−0.35,0.57) | 0.64 | 0.90 | −0.19 | (−0.54,0.15) | 0.27 | 0.89 |
Male (n = 75) | 0.05 | (−0.37,0.47) | 0.81 | −0.17 | (−0.55,0.21) | 0.38 | |||
ln(DHEA) | Female (n = 62) | 0.1 | (−0.18,0.39) | 0.48 | 0.74 | −0.04 | (−0.26,0.17) | 0.70 | 0.84 |
Male (n = 75) | 0.02 | (−0.31,0.36) | 0.88 | −0.01 | (−0.31,0.32) | 0.97 |